<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984850</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2861</org_study_id>
    <nct_id>NCT04984850</nct_id>
  </id_info>
  <brief_title>Oncology - Bolstering Oral Agent Reporting Related to Distress</brief_title>
  <acronym>ON-BOARD</acronym>
  <official_title>Feasibility, Acceptability, and Potential Effects of a Comprehensive Oral Chemotherapy Intervention on Medication Adherence Self-efficacy, Medication Adherence, and Symptom Distress: A Pilot Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rossy Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals on oral chemotherapy (OC) often face many challenges requiring adequate&#xD;
      informational support, monitoring, and management. This pilot randomized control trial (RCT)&#xD;
      aims to assess the feasibility, acceptability, and preliminary effects of a comprehensive OC&#xD;
      intervention on medication adherence self-efficacy, medication adherence, and symptom&#xD;
      distress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Following baseline, participants randomized immediately to receive either the intervention plus usual care (experimental group, n = 26) or usual care only (control group, n = 26).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Medication adherence self-efficacy</measure>
    <time_frame>Five months</time_frame>
    <description>Measured with the Medication Adherence Self-Efficacy Scale (MASES) was developed by Ogedge et al. (2003), evaluates the confidence of patients to take their medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication adherence and symptom distress</measure>
    <time_frame>Five months</time_frame>
    <description>Medication Adherence Self-Efficacy Scale (MASES) was developed by Ogedge et al. (2003). It evaluates the confidence of patients to take their medication. The scale has a Cronbach alpha of 0.95 and contains 25 items, each are rated from 1 (not at all sure) to 3 (extremely sure), a total score calculated by summing the responses. The scale initially developed within the context of anti-hypertensive medications has been previously modified and adapted for oncology oral agents with 24 items. For the current study, the oral agent scale was further modified with 20 items to be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Oral Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Intervention plus usual care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral chemotherapy information and support</intervention_name>
    <description>Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.</description>
    <arm_group_label>Intervention plus usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Diagnosis of cancer, any stage&#xD;
&#xD;
          -  Being followed by a care team at the affiliated hospital centre&#xD;
&#xD;
          -  About to start or within the first cycle of oral chemotherapy treatment&#xD;
&#xD;
          -  Has a computer/tablet/smartphone device with internet&#xD;
&#xD;
          -  The ability to communicate, read, and write in English or French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving IV chemotherapy, immunotherapy and/or targeted therapy&#xD;
&#xD;
          -  Significant physical or cognitive limitations that would prevent ability to&#xD;
             participate in study as reported by patient, primary healthcare provider, or research&#xD;
             staff&#xD;
&#xD;
          -  At imminent &quot;end-of-life&quot;&#xD;
&#xD;
          -  Participating in an ongoing clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Saima Ahmed</last_name>
    <phone>514-690-7860</phone>
    <email>Saima.ahmed.ccomtl@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacqueline Vachon</last_name>
    <phone>514-398-8977</phone>
    <email>Loiselle.Lab.ccomtl@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Carmen G. Loiselle, N., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Oral chemotherapy</keyword>
  <keyword>medication adherence</keyword>
  <keyword>self-efficacy</keyword>
  <keyword>pilot randomized control trial</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

